Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

References

• El-SeragHB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127. doi:10.1056/NEJMra100168321992124
   PubMed Web of Science ®Google Scholar
• FerlayJ, ColombetM, SoerjomataramI, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.3193730350310
   PubMed Web of Science ®Google Scholar
• AllemaniC, WeirHK, CarreiraH, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010. doi:10.1016/S0140-6736(14)62038-925467588
   PubMed Web of Science ®Google Scholar
• ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• ChengAL, KangYK, ChenZ, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-719095497
   PubMed Web of Science ®Google Scholar
• LlovetJM, RicciS, MazzaferroV, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa070885718650514
   PubMed Web of Science ®Google Scholar
• KudoM, FinnRS, QinS, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-129433850
   PubMed Web of Science ®Google Scholar
• QinS, BaiY, LimHY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501–3508. doi:10.1200/JCO.2012.44.564323980077
   PubMed Web of Science ®Google Scholar
• QinS, ChengY, LiangJ, et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014;19(11):1169–1178. doi:10.1634/theoncologist.2014-019025223462
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology. hepatobiliary cancers. Version 5; 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed 302, 2021.
   Google Scholar
• BruixJ, QinS, MerleP, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-927932229
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGK, MeyerT, ChengAL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa171700229972759
   PubMed Web of Science ®Google Scholar
• ZhuAX, KangYK, YenCJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-930665869
   PubMed Web of Science ®Google Scholar
• El-KhoueiryAB, SangroB, YauT, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-228434648
   PubMed Web of Science ®Google Scholar
• YauT, HsuC, KimTY, et al. Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis. J Hepatol. 2019;71(3):543–552. doi:10.1016/j.jhep.2019.05.01431176752
   PubMed Web of Science ®Google Scholar
• ZhuAX, FinnRS, EdelineJ, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-629875066
   PubMed Web of Science ®Google Scholar
• QinS, RenZ, MengZ, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–580. doi:10.1016/S1470-2045(20)30011-532112738
   PubMed Web of Science ®Google Scholar
• YauT, ParkJW, FinnRS, et al. LBA38_PR - CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874–v875. doi:10.1093/annonc/mdz394.029
   Web of Science ®Google Scholar
• FinnRS, RyooBY, MerleP, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III Trial. J Clin Oncol. 2020;38(3):193–202. doi:10.1200/JCO.19.0130731790344
   PubMed Web of Science ®Google Scholar
• TianM, ShiY, LiuW, FanJ. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Sci China Life Sci. 2019;62(9):1138–1143. doi:10.1007/s11427-018-9446-231119560
   PubMed Web of Science ®Google Scholar
• ChenM, LiL, LiH, et al. Treatment patterns and clinical outcomes for patients with hepatocellular carcinoma from China: a sub-analysis of the Global Hepatocellular Carcinoma BRIDGE Study. J Hepatol. 2017;66(1):S455–S456. doi:10.1016/S0168-8278(17)31291-6
   Web of Science ®Google Scholar
• FinnRS, IkedaM, ZhuAX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.0080832716739
   PubMed Web of Science ®Google Scholar
• FinnRS, QinS, IkedaM, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa191574532402160
   PubMed Web of Science ®Google Scholar
• LangerCJ, GadgeelSM, BorghaeiH, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508. doi:10.1016/S1470-2045(16)30498-327745820
   PubMed Web of Science ®Google Scholar
• BorghaeiH, LangerCJ, GadgeelS, et al. 24-Month Overall Survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2019;14(1):124–129. doi:10.1016/j.jtho.2018.08.00430138764
   PubMed Web of Science ®Google Scholar
• Paz-AresL, LuftA, VicenteD, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa181086530280635
   PubMed Web of Science ®Google Scholar
• FangW, YangY, MaY, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338–1350. doi:10.1016/S1470-2045(18)30495-930213452
   PubMed Web of Science ®Google Scholar
• LvJW, LiJY, LuoLN, WangZX, ChenYP. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials. J Immunother Cancer. 2019;7(1):159. doi:10.1186/s40425-019-0636-731238988
   PubMed Web of Science ®Google Scholar
• PetersS, KimAW, SolomonB, et al. IMpower030: phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. Ann Oncol. 2019;30:ii30. doi:10.1093/annonc/mdz064.014
   Google Scholar
• ZhouC, ChenG, HuangY, et al. OA04.03 A randomized phase 3 study of camrelizumab plus chemotherapy as 1st Line therapy for advanced/metastatic non-squamous non-small cell lung cancer. J Thoracic Oncol. 2019;14(10):S215–S216. doi:10.1016/j.jtho.2019.08.425
   Web of Science ®Google Scholar
• WangQ, JuX, WangJ, FanY, RenM, ZhangH. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett. 2018;438:17–23. doi:10.1016/j.canlet.2018.08.02830217563
   PubMed Web of Science ®Google Scholar
• EmensLA, MiddletonG. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443. doi:10.1158/2326-6066.CIR-15-006425941355
   PubMed Web of Science ®Google Scholar
• GrimaldiA, CammarataI, MartireC, et al. Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. Commun Biol. 2020;3(1):85. doi:10.1038/s42003-020-0811-x32099064
   PubMed Web of Science ®Google Scholar
• JafariS, LavasanifarA, HejaziMS, Maleki-DizajiN, MesgariM, MolaviO. STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells. Daru. 2020;28(1):159–169. doi:10.1007/s40199-020-00326-z31942696
   PubMed Web of Science ®Google Scholar
• TuK, DengH, KongL, et al. Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death. ACS Appl Mater Interfaces. 2020;12(14):16018–16030. doi:10.1021/acsami.9b2308432192326
   PubMed Web of Science ®Google Scholar
• ChenDS, MellmanI. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature2134928102259
   PubMed Web of Science ®Google Scholar
• RebeC, DemontouxL, PilotT, GhiringhelliF. Platinum derivatives effects on anticancer immune response. Biomolecules. 2019;10(1). doi:10.3390/biom10010013
   Web of Science ®Google Scholar
• WangW, WuL, ZhangJ, WuH, HanE, GuoQ. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. Biochem Biophys Res Commun. 2017;487(1):1–7. doi:10.1016/j.bbrc.2016.12.18028042031
   PubMed Web of Science ®Google Scholar
• WangF, QinS, SunX, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol. 2020;13(1):47. doi:10.1186/s13045-020-00886-232393323
   PubMed Web of Science ®Google Scholar